Liposomes encapsulating lbp, methods of making and use thereof

By encapsulating LBP in DPPC phospholipid bilayer liposomes, combined with membrane hydration and extrusion methods, the issues of lung targeting and immune safety of LBP in the treatment of acute lung injury were resolved, achieving stable delivery and non-inflammatory release of LBP, and significantly improving the therapeutic effect.

CN122123979APending Publication Date: 2026-06-02ANHUI MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
ANHUI MEDICAL UNIV
Filing Date
2026-04-30
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Existing liposome delivery technologies have difficulty in stably encapsulating structure-sensitive endogenous immunomodulatory proteins such as LBP, resulting in insufficient lung targeting and immune safety in the treatment of acute lung injury, and direct administration may trigger systemic inflammatory responses.

Method used

Using phospholipid bilayer liposomes containing DPPC, LBP is encapsulated by a combination of thin-film hydration and extrusion. The synergistic effect of DPPC and pulmonary surfactant enables targeted lung delivery and non-inflammatory release of LBP.

Benefits of technology

It achieves stable encapsulation and targeted delivery of LBP to the lungs, reduces lung tissue damage, avoids systemic inflammatory response, and significantly improves the treatment effect of acute lung injury.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122123979A_ABST
    Figure CN122123979A_ABST
Patent Text Reader

Abstract

This application discloses liposomes encapsulating LBP, their preparation method, and applications, belonging to the field of biomedical technology. The liposome comprises a phospholipid bilayer, with LBP encapsulated within the lumen of the phospholipid bilayer. The phospholipid bilayer is formed of a mixture of lipids, consisting of cationic lipids, neutral accessory lipids, and sterols, wherein the neutral accessory lipid is dipalmitoyllecithin. This liposome achieves a synergistic protective effect in the treatment of acute lung injury through a strategy of combining DPPC in the lipid membrane with LBP encapsulation, exhibiting excellent lung targeting and immune safety, thereby providing a new approach for the application of LBP protein in the treatment of acute lung injury and improving the therapeutic efficacy of acute lung injury.
Need to check novelty before this filing date? Find Prior Art